drugset / Trial / NCT01511315

The Quality of Life Study in Psoriasis Patients After Ustekinumab Treatment

NCT01511315

Phase 4 Completed 36 enrolled University of California, San Francisco
NaSingle-groupOpen-labelTreatment

Summary

This study aims to see if patient quality of life can be approved after treatment with an injectable medication called ustekinumab for the treatment of generalized psoriasis. The investigators hypothesize that the investigators will see improvement in quality of life.

Timeline

Start
2012-03
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Ustekinumab Monoclonal antibody Subcutaneous

Indications